anti vegf ab  (R&D Systems)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Name:
    Mouse VEGF164 Antibody
    Description:
    The Mouse VEGF164 Antibody from R D Systems is a goat polyclonal antibody to VEGF This antibody reacts with mouse The Mouse VEGF164 Antibody has been validated for the following applications Western Blot Immunohistochemistry Neutralization ELISA Capture Matched Antibody Pair
    Catalog Number:
    AF-493-NA
    Price:
    375
    Category:
    Primary Antibodies
    Applications:
    Western Blot, Immunohistochemistry, Neutralization, ELISA Capture (Matched Antibody Pair)
    Purity:
    Antigen Affinity-purified
    Conjugate:
    Unconjugated
    Immunogen:
    S. frugiperda insect ovarian cell line Sf 21-derived recombinant mouse VEGF164, Ala27-Arg190, Accession # AAA40547
    Size:
    100 ug
    Host:
    Goat
    Isotype:
    IgG
    Buy from Supplier


    Structured Review

    R&D Systems anti vegf ab
    Mouse VEGF164 Antibody
    The Mouse VEGF164 Antibody from R D Systems is a goat polyclonal antibody to VEGF This antibody reacts with mouse The Mouse VEGF164 Antibody has been validated for the following applications Western Blot Immunohistochemistry Neutralization ELISA Capture Matched Antibody Pair
    https://www.bioz.com/result/anti vegf ab/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti vegf ab - by Bioz Stars, 2021-03
    94/100 stars

    Images

    Related Articles

    Injection:

    Article Title: Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina
    Article Snippet: .. The following compounds (all diluted in 1× PBS) were injected intravitreally immediately after laser pulse application: 1.5 μl of either Aflibercept (10 μg/μl, Eylea, Bayer HealthCare), anti-VEGF-A (5 μg/μl, goat anti-mouse VEGF-AA IgG, AF493-NA, R & D Systems), anti-PGF (5 μg/μl, polyclonal rabbit anti-PGF antibody, ab9542, Abcam), anti-VEGF and anti-PGF combined (each 5 μg/μl), or IgG control (10 μg/μl, normal goat IgG control (AB-108-C, R & D systems). ..

    Article Title: IKK2 Inhibition Attenuates Laser-Induced Choroidal Neovascularization
    Article Snippet: We observed that retrobulbar injection achieved a similar inhibitory effect as intravitreal injection, although the retrobulbar route required a larger injection volume (20 μl of 10 mM TPCA-1 compared to 2 μl of 10 mM TPCA-1) ( ). .. We also observed that the inhibitory effect of retrobulbar injected 10 mM TPCA-1 was comparable to intravitreal anti-mouse VEGF 164 polyclonal antibody (R & D System, CatAF-493-NA) with regard to CNV size ( ). ..

    Purification:

    Article Title: Combination of apolipoprotein-A-I/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice
    Article Snippet: Intravitreal delivery Intravitreal injection in mice was performed as previously described with an injection volume of 1.2 μL. .. For most experiments, 2.4 µg AIBP, 10 µg apoA-I, 5 ng anti-VEGF antibody (AF-493-NA, R & D Systems), 12.4 µg BSA, and 5 ng purified goat IgG (control for anti-VEGF antibody) were delivered individually or in combination unless otherwise indicated. .. For antibody neutralization of AIBP, 1.3 µg affinity purified rabbit anti-AIBP polyclonal antibody was delivered by intravitreal injection immediately after laser photocoagulation to WT mice.

    Mouse Assay:

    Article Title: Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy
    Article Snippet: .. For antibodies, the OIR mice were anesthetized at P12 and received intravitreal injections of anti‐Sema4D neutralizing antibody (2 μg per eye, BMA‐12), anti‐VEGF neutralizing antibody (2 μg per eye, AF‐493‐NA, R & D Systems) alone or combinedly. .. For adenoviruses in OIR model, adenoviruses (1 μl) containing double‐floxed Cre‐inducible GFP and mir30‐shRNA were intravitreally injected into Tie2‐Cre mice at P7 before exposure to 75% O2, the retinas were harvested at P17.

    Enzyme-linked Immunosorbent Assay:

    Article Title: Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma
    Article Snippet: Immunoreactive proteins were visualized using the enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ). .. Capture enzyme-linked immunosorbent assay was performed using anti-mouse VEGF antibody (BAF493, R & D Systems) as capture antibody and anti-VEGF164 biotinylated antibody (AF-493-NA, R & D Systems) as detection antibody in the concentrations described by the manufacturer. .. The reaction plate was revealed by the 2,2′-aziro-bis-(3-ethylbenzothiazoline-g-sulfonic acid) diammonium salt (ABTS) detection system (Roche) after streptavidin-horseradish peroxidase (Pharmingen) incubation.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    R&D Systems anti vegf bevacizumab similar antibody
    Blockade of both <t>VEGF/VEGFR2</t> and Dll4/Notch1 signaling pathways by HD105 bispecific antibody leads to inhibition of each signaling-induced cellular response. The HD105 bispecific antibody inhibited both the VEGF/VEGFR2 and the Dll4/Notch1 signaling pathways in HUVECs (A). The VEGF/VEGFR2 signaling pathway was monitored by the activation of VEGFR2 and ERK (phosphorylation). The Dll4/Notch1 signaling pathway was monitored by the generation of NICD (Notch-induced intracellular domain). HUVEC sprouting assays were performed in a fibrin gel in the presence of PBS (B), anti-VEGF <t>(bevacizumab-similar)</t> antibody (C), anti-Dll4 antibody (D), or HD105 bispecific antibody (E). Representative images show sprouting tip cells of HUVECs from the beads under basal media (B, arrowheads) and more sprouting under anti-Dll4 antibody treatment (D, arrows) but much less sprouting under anti-VEGF antibody (C) or HD105 bispecific antibody treatment (E). Scale bar (B-E), 150 μm. The bar graph (F) shows the measurement of sprouting HUVECs at 225 μm from beads (n = 20 beads/group, mean ± SE). *, P
    Anti Vegf Bevacizumab Similar Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti vegf bevacizumab similar antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti vegf bevacizumab similar antibody - by Bioz Stars, 2021-03
    93/100 stars
      Buy from Supplier

    97
    R&D Systems goat anti vegf
    Representative bands obtained by western blot analysis of <t>VEGF</t> (25 kDa), <t>VEGFR1</t> (120 kDa) and VEGFR2 (180 kDa) in corpus cavernosum samples of control ( C ), green tea ( GT ) and green tea extract ( EGT )-treated rats. Semi-quantitative
    Goat Anti Vegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti vegf/product/R&D Systems
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    goat anti vegf - by Bioz Stars, 2021-03
    97/100 stars
      Buy from Supplier

    93
    R&D Systems anti vegf antibody
    Effect of <t>VSL#3</t> treatment on protein production of different growth factors in rats with acetic acid induced gastric ulcers. Protein levels in tissue homogenates was measured by ELISA for <t>VEGF</t> [Top], TGF-β [Middle] and EGF [Bottom] in control (Blue), VSL#3 low (light green) and high (dark green) dose treated animals on days 7 and 14 of treatment. Protein levels in all groups are represented as pg/mg of tissue. Data shown are the means ± SEM of 6 animals/day. P values for all significant comparison ( p
    Anti Vegf Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti vegf antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti vegf antibody - by Bioz Stars, 2021-03
    93/100 stars
      Buy from Supplier

    95
    R&D Systems monoclonal anti human vegf antibody
    Angiopoietin and <t>VEGF</t> expression in <t>Colo205</t> and other tumor xenografts
    Monoclonal Anti Human Vegf Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal anti human vegf antibody/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal anti human vegf antibody - by Bioz Stars, 2021-03
    95/100 stars
      Buy from Supplier

    Image Search Results


    Blockade of both VEGF/VEGFR2 and Dll4/Notch1 signaling pathways by HD105 bispecific antibody leads to inhibition of each signaling-induced cellular response. The HD105 bispecific antibody inhibited both the VEGF/VEGFR2 and the Dll4/Notch1 signaling pathways in HUVECs (A). The VEGF/VEGFR2 signaling pathway was monitored by the activation of VEGFR2 and ERK (phosphorylation). The Dll4/Notch1 signaling pathway was monitored by the generation of NICD (Notch-induced intracellular domain). HUVEC sprouting assays were performed in a fibrin gel in the presence of PBS (B), anti-VEGF (bevacizumab-similar) antibody (C), anti-Dll4 antibody (D), or HD105 bispecific antibody (E). Representative images show sprouting tip cells of HUVECs from the beads under basal media (B, arrowheads) and more sprouting under anti-Dll4 antibody treatment (D, arrows) but much less sprouting under anti-VEGF antibody (C) or HD105 bispecific antibody treatment (E). Scale bar (B-E), 150 μm. The bar graph (F) shows the measurement of sprouting HUVECs at 225 μm from beads (n = 20 beads/group, mean ± SE). *, P

    Journal: mAbs

    Article Title: Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis

    doi: 10.1080/19420862.2016.1171432

    Figure Lengend Snippet: Blockade of both VEGF/VEGFR2 and Dll4/Notch1 signaling pathways by HD105 bispecific antibody leads to inhibition of each signaling-induced cellular response. The HD105 bispecific antibody inhibited both the VEGF/VEGFR2 and the Dll4/Notch1 signaling pathways in HUVECs (A). The VEGF/VEGFR2 signaling pathway was monitored by the activation of VEGFR2 and ERK (phosphorylation). The Dll4/Notch1 signaling pathway was monitored by the generation of NICD (Notch-induced intracellular domain). HUVEC sprouting assays were performed in a fibrin gel in the presence of PBS (B), anti-VEGF (bevacizumab-similar) antibody (C), anti-Dll4 antibody (D), or HD105 bispecific antibody (E). Representative images show sprouting tip cells of HUVECs from the beads under basal media (B, arrowheads) and more sprouting under anti-Dll4 antibody treatment (D, arrows) but much less sprouting under anti-VEGF antibody (C) or HD105 bispecific antibody treatment (E). Scale bar (B-E), 150 μm. The bar graph (F) shows the measurement of sprouting HUVECs at 225 μm from beads (n = 20 beads/group, mean ± SE). *, P

    Article Snippet: Increasing concentrations of anti-VEGF (bevacizumab-similar) antibody or HD105 bispecific antibody were mixed with equal volumes of His-tagged recombinant human VEGFR2/Fc (1.65 µg/ml, R & D Systems).

    Techniques: Inhibition, Activation Assay

    Suppression of tumor angiogenesis in cancer xenograft models by HD105 bispecific antibody. Fluorescence micrographs compare the vasculature of A549 human lung cancer tissues in xenograft mice after treatment with PBS (A), anti-VEGF (bevacizumab-similar) antibody (B), anti-mouse Dll4 antibody (C), or mouse HD105 bispecific antibody (D). Scale bar (A-D), 50 μm. The tumor vasculature was stained for CD31 immunoreactivity (green), and the vascular basement was stained for type IV collagen (red). Tumor vessels were decreased after treatment with anti-VEGF (bevacizumab-similar) antibody or mouse HD105 bispecific antibody, whereas tumor vessels were markedly increased after treatment with anti-mouse Dll4 antibody compared to PBS. Higher-resolution images compare the phenotype changes of tumor vessels in detail after PBS (E), anti-VEGF (bevacizumab-similar) antibody (F), anti-mouse Dll4 antibody (G), or mouse HD105 bispecific antibody treatment (H). Scale bar (E-H), 20 μm. The tumor vasculature was stained for CD31 immunoreactivity (red), and the perivascular pericyte was stained for NG2 (green). The nuclei of the tumor tissues were stained by DAPI (4′,6-diamidino-2-phenylindole). Tumor vessels after treatment with anti-mouse Dll4 antibody were conspicuously thinner and more branched than the tumor vessels of other groups. Bar graph (I) measuring tumor vessel density of A549 tumor tissues in xenograft mice confirms the conspicuous increase of tumor vessels after anti-mouse Dll4 antibody treatment but decreases after anti-VEGF (bevacizumab-similar) antibody, mouse HD105 bispecific antibody, or combination treatment with anti-mouse Dll4 antibody and anti-VEGF (bevacizumab-similar) antibody. †, P

    Journal: mAbs

    Article Title: Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis

    doi: 10.1080/19420862.2016.1171432

    Figure Lengend Snippet: Suppression of tumor angiogenesis in cancer xenograft models by HD105 bispecific antibody. Fluorescence micrographs compare the vasculature of A549 human lung cancer tissues in xenograft mice after treatment with PBS (A), anti-VEGF (bevacizumab-similar) antibody (B), anti-mouse Dll4 antibody (C), or mouse HD105 bispecific antibody (D). Scale bar (A-D), 50 μm. The tumor vasculature was stained for CD31 immunoreactivity (green), and the vascular basement was stained for type IV collagen (red). Tumor vessels were decreased after treatment with anti-VEGF (bevacizumab-similar) antibody or mouse HD105 bispecific antibody, whereas tumor vessels were markedly increased after treatment with anti-mouse Dll4 antibody compared to PBS. Higher-resolution images compare the phenotype changes of tumor vessels in detail after PBS (E), anti-VEGF (bevacizumab-similar) antibody (F), anti-mouse Dll4 antibody (G), or mouse HD105 bispecific antibody treatment (H). Scale bar (E-H), 20 μm. The tumor vasculature was stained for CD31 immunoreactivity (red), and the perivascular pericyte was stained for NG2 (green). The nuclei of the tumor tissues were stained by DAPI (4′,6-diamidino-2-phenylindole). Tumor vessels after treatment with anti-mouse Dll4 antibody were conspicuously thinner and more branched than the tumor vessels of other groups. Bar graph (I) measuring tumor vessel density of A549 tumor tissues in xenograft mice confirms the conspicuous increase of tumor vessels after anti-mouse Dll4 antibody treatment but decreases after anti-VEGF (bevacizumab-similar) antibody, mouse HD105 bispecific antibody, or combination treatment with anti-mouse Dll4 antibody and anti-VEGF (bevacizumab-similar) antibody. †, P

    Article Snippet: Increasing concentrations of anti-VEGF (bevacizumab-similar) antibody or HD105 bispecific antibody were mixed with equal volumes of His-tagged recombinant human VEGFR2/Fc (1.65 µg/ml, R & D Systems).

    Techniques: Fluorescence, Mouse Assay, Staining

    Simultaneous binding to VEGF and Dll4 by HD105 bispecific antibody leads to effective blockade of VEGF/VEGFR2 and Dll4/Notch1 interactions. The HD105 bispecific antibody was constructed of the C-terminal of the anti-VEGF (bevacizumab-similar) IgG backbone linked with a single-chain Fv targeting Dll4 (A). The binding affinity of the HD105 bispecific antibody against human VEGF or human Dll4 was determined by Biacore assays (B) and ELISAs (C, D). The K D values of each antibody against VEGF or Dll4 are summarized in Table (B). The HD105 bispecific antibody (closed circle) dose-dependently bound to human VEGF (C) or Dll4 (D). In addition, the HD105 bispecific antibody simultaneously bound to each antigen, human VEGF and human Dll4, in dual-antigen capture ELISAs (E). The anti-Dll4 antibody (open circle in C) or the anti-VEGF (bevacizumab-similar) antibody (open circle in D, E) was used as negative control. Competitive ELISAs demonstrated that the HD105 bispecific antibody inhibited the interaction between VEGF/VEGFR2 (F) or Dll4/Notch1 (G) in a dose-dependent manner. The EC 50 (half maximal effective concentration) values of the anti-VEGF (bevacizumab-similar) antibody (open circle) and HD105 bispecific antibody (closed circle) for VEGF/VEGFR2 inhibition were 2.98 ± 0.5 nM and 2.84 ± 0.41 nM, respectively (F). The EC 50 values of the anti-Dll4 antibody (open circle) and HD105 bispecific antibody (closed circle) were 0.65 ± 0.06 nM and 1.14 ± 0.06 nM, respectively (G).

    Journal: mAbs

    Article Title: Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis

    doi: 10.1080/19420862.2016.1171432

    Figure Lengend Snippet: Simultaneous binding to VEGF and Dll4 by HD105 bispecific antibody leads to effective blockade of VEGF/VEGFR2 and Dll4/Notch1 interactions. The HD105 bispecific antibody was constructed of the C-terminal of the anti-VEGF (bevacizumab-similar) IgG backbone linked with a single-chain Fv targeting Dll4 (A). The binding affinity of the HD105 bispecific antibody against human VEGF or human Dll4 was determined by Biacore assays (B) and ELISAs (C, D). The K D values of each antibody against VEGF or Dll4 are summarized in Table (B). The HD105 bispecific antibody (closed circle) dose-dependently bound to human VEGF (C) or Dll4 (D). In addition, the HD105 bispecific antibody simultaneously bound to each antigen, human VEGF and human Dll4, in dual-antigen capture ELISAs (E). The anti-Dll4 antibody (open circle in C) or the anti-VEGF (bevacizumab-similar) antibody (open circle in D, E) was used as negative control. Competitive ELISAs demonstrated that the HD105 bispecific antibody inhibited the interaction between VEGF/VEGFR2 (F) or Dll4/Notch1 (G) in a dose-dependent manner. The EC 50 (half maximal effective concentration) values of the anti-VEGF (bevacizumab-similar) antibody (open circle) and HD105 bispecific antibody (closed circle) for VEGF/VEGFR2 inhibition were 2.98 ± 0.5 nM and 2.84 ± 0.41 nM, respectively (F). The EC 50 values of the anti-Dll4 antibody (open circle) and HD105 bispecific antibody (closed circle) were 0.65 ± 0.06 nM and 1.14 ± 0.06 nM, respectively (G).

    Article Snippet: Increasing concentrations of anti-VEGF (bevacizumab-similar) antibody or HD105 bispecific antibody were mixed with equal volumes of His-tagged recombinant human VEGFR2/Fc (1.65 µg/ml, R & D Systems).

    Techniques: Binding Assay, Construct, Negative Control, Concentration Assay, Inhibition

    Increase in apoptotic tumor cells in cancer xenograft models treated with HD105 bispecific antibody. Fluorescence micrographs show apoptotic cells stained for activated caspase-3 antibody (red) in SCH human gastric cancer tissues in xenograft mice after treatment with PBS (A), anti-VEGF (bevacizumab-similar) antibody (B), anti-mouse Dll4 antibody (C), and mouse HD105 bispecific antibody (D and E). Scale bar (A-D), 50 μm; (E), 20 μm. Nuclei of the tumor tissues were stained by DAPI (4′,6-diamidino-2-phenylindole, blue). The higher-resolution image confirms that activated caspase-3 antibody was stained in the cytoplasm of the apoptotic cells after mouse HD105 bispecific antibody treatment (E). The bar graph (F) measuring the cell density of apoptotic cells in SCH cancer tissues confirms the significant increase in apoptotic cells after mouse HD105 bispecific antibody treatment. *, P

    Journal: mAbs

    Article Title: Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis

    doi: 10.1080/19420862.2016.1171432

    Figure Lengend Snippet: Increase in apoptotic tumor cells in cancer xenograft models treated with HD105 bispecific antibody. Fluorescence micrographs show apoptotic cells stained for activated caspase-3 antibody (red) in SCH human gastric cancer tissues in xenograft mice after treatment with PBS (A), anti-VEGF (bevacizumab-similar) antibody (B), anti-mouse Dll4 antibody (C), and mouse HD105 bispecific antibody (D and E). Scale bar (A-D), 50 μm; (E), 20 μm. Nuclei of the tumor tissues were stained by DAPI (4′,6-diamidino-2-phenylindole, blue). The higher-resolution image confirms that activated caspase-3 antibody was stained in the cytoplasm of the apoptotic cells after mouse HD105 bispecific antibody treatment (E). The bar graph (F) measuring the cell density of apoptotic cells in SCH cancer tissues confirms the significant increase in apoptotic cells after mouse HD105 bispecific antibody treatment. *, P

    Article Snippet: Increasing concentrations of anti-VEGF (bevacizumab-similar) antibody or HD105 bispecific antibody were mixed with equal volumes of His-tagged recombinant human VEGFR2/Fc (1.65 µg/ml, R & D Systems).

    Techniques: Fluorescence, Staining, Mouse Assay

    Representative bands obtained by western blot analysis of VEGF (25 kDa), VEGFR1 (120 kDa) and VEGFR2 (180 kDa) in corpus cavernosum samples of control ( C ), green tea ( GT ) and green tea extract ( EGT )-treated rats. Semi-quantitative

    Journal:

    Article Title: Does regular consumption of green tea influence expression of vascular endothelial growth factor and its receptor in aged rat erectile tissue? Possible implications for vasculogenic erectile dysfunction progression

    doi: 10.1007/s11357-008-9051-6

    Figure Lengend Snippet: Representative bands obtained by western blot analysis of VEGF (25 kDa), VEGFR1 (120 kDa) and VEGFR2 (180 kDa) in corpus cavernosum samples of control ( C ), green tea ( GT ) and green tea extract ( EGT )-treated rats. Semi-quantitative

    Article Snippet: Immunofluorescence detection of VEGF/VEGFR1 and VEGFR1/VEGFR2 was also performed, starting with a mix of rabbit anti-VEGFR1 (Lab Vision Corporation, Fremont, CA) with goat anti-VEGF (R & D Systems) or mouse anti-VEGFR2 (Santa Cruz Biotechnology) primary antibodies, followed by a suitable mix of secondary antibodies, anti-rabbit conjugated with Alexa 488 (green) with anti-goat or anti-mouse conjugated with Alexa 568 (red) both diluted 1/500.

    Techniques: Western Blot

    Confocal microscopy immunofluorescence of VEGF ( red ) and VEGFR1 ( green ) in corpus cavernosum of rats. Double-labelling was observed in the muscle layer at the vessel periphery ( white arrow ) in control (C) ( a ), green tea (GT) ( b ) and green tea extract

    Journal:

    Article Title: Does regular consumption of green tea influence expression of vascular endothelial growth factor and its receptor in aged rat erectile tissue? Possible implications for vasculogenic erectile dysfunction progression

    doi: 10.1007/s11357-008-9051-6

    Figure Lengend Snippet: Confocal microscopy immunofluorescence of VEGF ( red ) and VEGFR1 ( green ) in corpus cavernosum of rats. Double-labelling was observed in the muscle layer at the vessel periphery ( white arrow ) in control (C) ( a ), green tea (GT) ( b ) and green tea extract

    Article Snippet: Immunofluorescence detection of VEGF/VEGFR1 and VEGFR1/VEGFR2 was also performed, starting with a mix of rabbit anti-VEGFR1 (Lab Vision Corporation, Fremont, CA) with goat anti-VEGF (R & D Systems) or mouse anti-VEGFR2 (Santa Cruz Biotechnology) primary antibodies, followed by a suitable mix of secondary antibodies, anti-rabbit conjugated with Alexa 488 (green) with anti-goat or anti-mouse conjugated with Alexa 568 (red) both diluted 1/500.

    Techniques: Confocal Microscopy, Immunofluorescence

    Effect of VSL#3 treatment on protein production of different growth factors in rats with acetic acid induced gastric ulcers. Protein levels in tissue homogenates was measured by ELISA for VEGF [Top], TGF-β [Middle] and EGF [Bottom] in control (Blue), VSL#3 low (light green) and high (dark green) dose treated animals on days 7 and 14 of treatment. Protein levels in all groups are represented as pg/mg of tissue. Data shown are the means ± SEM of 6 animals/day. P values for all significant comparison ( p

    Journal: PLoS ONE

    Article Title: The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor

    doi: 10.1371/journal.pone.0058671

    Figure Lengend Snippet: Effect of VSL#3 treatment on protein production of different growth factors in rats with acetic acid induced gastric ulcers. Protein levels in tissue homogenates was measured by ELISA for VEGF [Top], TGF-β [Middle] and EGF [Bottom] in control (Blue), VSL#3 low (light green) and high (dark green) dose treated animals on days 7 and 14 of treatment. Protein levels in all groups are represented as pg/mg of tissue. Data shown are the means ± SEM of 6 animals/day. P values for all significant comparison ( p

    Article Snippet: The effect of neutralizing anti-VEGF antibody on gastric ulcer healing induced by VSL#3 To evaluate the effect of neutralizing anti-VEGF antibody on gastric ulcer healing promoted by VSL#3, four groups of animals were used namely, control, neutralizing VEGF antibody (R & D systems), VSL#3 high dose + IgG (isoform antibody, R & D systems), and VSL#3 high dose + neutralizing VEGF antibody (R & D systems).

    Techniques: Enzyme-linked Immunosorbent Assay

    Effect of VSL#3 treatment on gene expression of different growth factors in rats with acetic acid induced gastric ulcers. The relative gene expression levels determined by real time PCR for VEGF [Top], TGF-β [Middle] and EGF [Bottom] using mRNA extracted from control (Blue), VSL#3 low (light green) and high (dark green) dose treated animals on day 7 and day 14 of treatment. Expression levels of all genes were normalized using GAPDH as housekeeping gene. The mRNA expression is graphed as fold change in ulcerated tissue over non-ulcerated tissue. Data shown are the means ± SEM of 6 animals/day. P values for all significant comparison ( p

    Journal: PLoS ONE

    Article Title: The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor

    doi: 10.1371/journal.pone.0058671

    Figure Lengend Snippet: Effect of VSL#3 treatment on gene expression of different growth factors in rats with acetic acid induced gastric ulcers. The relative gene expression levels determined by real time PCR for VEGF [Top], TGF-β [Middle] and EGF [Bottom] using mRNA extracted from control (Blue), VSL#3 low (light green) and high (dark green) dose treated animals on day 7 and day 14 of treatment. Expression levels of all genes were normalized using GAPDH as housekeeping gene. The mRNA expression is graphed as fold change in ulcerated tissue over non-ulcerated tissue. Data shown are the means ± SEM of 6 animals/day. P values for all significant comparison ( p

    Article Snippet: The effect of neutralizing anti-VEGF antibody on gastric ulcer healing induced by VSL#3 To evaluate the effect of neutralizing anti-VEGF antibody on gastric ulcer healing promoted by VSL#3, four groups of animals were used namely, control, neutralizing VEGF antibody (R & D systems), VSL#3 high dose + IgG (isoform antibody, R & D systems), and VSL#3 high dose + neutralizing VEGF antibody (R & D systems).

    Techniques: Expressing, Real-time Polymerase Chain Reaction

    Effect of anti-VEGF neutralizing antibody treatment on acetic acid induced gastric ulcer healing in rats. [ a ] The ulcer area (mm 2 ) plotted for animals with acetic acid induced gastric ulcer on days 7 and 14 of treatment with vehicle (Dark blue), VEGF neutralizing antibody alone (light blue), VSL#3 high dose + IgG (light green) and VSL#3 high dose + anti-VEGF neutralizing antibody (dark green). Data are represented as means ± SEM from 6 animals per day. Percent ulcer healing was calculated for animals treated with VEGF neutralizing antibody (light blue), VSL#3 high dose + IgG (light green) and VSL#3 high dose + anti-VEGF neutralizing antibody (dark green) in comparison to controls (dark blue). Significant p values are represented in the upper section of the plot. The percentage healing shown for the group treated with anti-VEGF antibody alone on Days 7 and 14 represent reduction in ulcer healing when compared to untreated controls. [ b ] Morphological view of acetic acid induced gastric ulcer on days 7 [Top] and 14 [Bottom] of treatment with vehicle (left), VSL#3 high dose + IgG (middle) and VSL#3 high dose + anti-VEGF neutralizing antibody (right).

    Journal: PLoS ONE

    Article Title: The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor

    doi: 10.1371/journal.pone.0058671

    Figure Lengend Snippet: Effect of anti-VEGF neutralizing antibody treatment on acetic acid induced gastric ulcer healing in rats. [ a ] The ulcer area (mm 2 ) plotted for animals with acetic acid induced gastric ulcer on days 7 and 14 of treatment with vehicle (Dark blue), VEGF neutralizing antibody alone (light blue), VSL#3 high dose + IgG (light green) and VSL#3 high dose + anti-VEGF neutralizing antibody (dark green). Data are represented as means ± SEM from 6 animals per day. Percent ulcer healing was calculated for animals treated with VEGF neutralizing antibody (light blue), VSL#3 high dose + IgG (light green) and VSL#3 high dose + anti-VEGF neutralizing antibody (dark green) in comparison to controls (dark blue). Significant p values are represented in the upper section of the plot. The percentage healing shown for the group treated with anti-VEGF antibody alone on Days 7 and 14 represent reduction in ulcer healing when compared to untreated controls. [ b ] Morphological view of acetic acid induced gastric ulcer on days 7 [Top] and 14 [Bottom] of treatment with vehicle (left), VSL#3 high dose + IgG (middle) and VSL#3 high dose + anti-VEGF neutralizing antibody (right).

    Article Snippet: The effect of neutralizing anti-VEGF antibody on gastric ulcer healing induced by VSL#3 To evaluate the effect of neutralizing anti-VEGF antibody on gastric ulcer healing promoted by VSL#3, four groups of animals were used namely, control, neutralizing VEGF antibody (R & D systems), VSL#3 high dose + IgG (isoform antibody, R & D systems), and VSL#3 high dose + neutralizing VEGF antibody (R & D systems).

    Techniques:

    Angiopoietin and VEGF expression in Colo205 and other tumor xenografts

    Journal: Cancer research

    Article Title: Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

    doi: 10.1158/0008-5472.CAN-09-1977

    Figure Lengend Snippet: Angiopoietin and VEGF expression in Colo205 and other tumor xenografts

    Article Snippet: CD1 nu/nu mice with implanted human Colo205 colon xenografts were treated with the Ang2-selective peptibody, L1-7(N) , and/or monoclonal anti-human VEGF antibody with a neutralization dose50 of 0.04–0.08 μg/mL against rat and human VEGF (clone 26503: R & D Systems; Minneapolis, MN).

    Techniques: Expressing

    Changes of tumor growth, weight and viable tumor cells after inhibition of Ang2, VEGF, or both

    Journal: Cancer research

    Article Title: Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

    doi: 10.1158/0008-5472.CAN-09-1977

    Figure Lengend Snippet: Changes of tumor growth, weight and viable tumor cells after inhibition of Ang2, VEGF, or both

    Article Snippet: CD1 nu/nu mice with implanted human Colo205 colon xenografts were treated with the Ang2-selective peptibody, L1-7(N) , and/or monoclonal anti-human VEGF antibody with a neutralization dose50 of 0.04–0.08 μg/mL against rat and human VEGF (clone 26503: R & D Systems; Minneapolis, MN).

    Techniques: Inhibition